Enzon Pharmaceuticals, Inc.
OTC: ENZN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard L. Feinstein
- Employees
- 1
- Headquarters
- Cranford, United States
- IPO year
- 1984
- Market cap
- $3.9M
- Website
- https://www.enzon.com
Loading ENZN…
Loading profile data…Frequently asked questions about ENZN
What does Enzon Pharmaceuticals, Inc. (ENZN) do?
Enzon Pharmaceuticals, Inc., along with its various subsidiaries, primarily focuses on the commercialization of pharmaceutical products. PegIntron is a key drug within its actively marketed portfolio. The company also maintains a specific marketing agreement for the medication Vicineum. Established in 1981, Enzon Pharmaceuticals is headquartered...
Where does ENZN trade?
Enzon Pharmaceuticals, Inc. (ENZN) trades on the Other OTC.
What sector is ENZN in?
Enzon Pharmaceuticals, Inc. (ENZN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Enzon Pharmaceuticals, Inc.?
Richard L. Feinstein is the chief executive officer of Enzon Pharmaceuticals, Inc. (ENZN).
Where is Enzon Pharmaceuticals, Inc. headquartered?
Enzon Pharmaceuticals, Inc. is headquartered in United States.
Does ENZN pay a dividend?
Enzon Pharmaceuticals, Inc. (ENZN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ENZN go public?
Enzon Pharmaceuticals, Inc. (ENZN) completed its initial public offering in 1984.